SG11201903182XA - 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer - Google Patents
6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancerInfo
- Publication number
- SG11201903182XA SG11201903182XA SG11201903182XA SG11201903182XA SG11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA SG 11201903182X A SG11201903182X A SG 11201903182XA
- Authority
- SG
- Singapore
- Prior art keywords
- cambridge
- building
- astrazeneca
- owg
- darwin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Lin (CouNR? ° 8000 6000 4000 2000 W O 20 18/077 630 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIPO I PCT ~~ll~~~~~~~~ 011101110VIIIOH olo olomo milo111110 Elio ow (10) International Publication Number WO 2018/077630 Al L 10 (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/497 (2006.01) A61K 31/4738 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2017/076191 (22) International Filing Date: 13 October 2017 (13.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/411,799 24 October 2016 (24.10.2016) US 62/435,159 16 December 2016 (16.12.2016) US (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). (72) Inventors: SCOTT, James, Stewart; AstraZeneca Dar- win Building, Cambridge Science Park, Milton Road Cambridge CB4 OWG (GB). BARLAAM, Bernard, Christophe; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 OWG (GB). YANG, Bin; AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451 (US). MOSS, Thomas, An- drew; AstraZeneca, Darwin Building Darwin Building, Cambridge Science Park, Milton Road Cambridgeshire CB4 OWG (GB). HUGHES, Samantha, Jayne; As- traZeneca Darwin Building, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 OWG (GB). NISSINK, Johannes, Wilhelmus, Maria; As- traZeneca, Darwin Building Cambridge Science Park, Mil- ton Road, Cambridge Canbridgeshire CB4 OWG (GB). O'DONOVAN, Daniel, Hillebrand; AstraZeneca Darwin Building, Cambridge Science Park, Milton Road, Cam- bridge Cambridgeshire CB4 OWG (GB). (74) Agent: COOK, Andrew, James; AstraZeneca Milstein Building, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (54) Title: 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER (57) : The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermedi- ates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders. (I) Figure 1: X-Ray Ponder Diffraction Pattern for Form A of 13-043- finoropropyhamtiffin 3 yl) 6 ((6S,8R) 8 methyl 7 (2,2,2 trifluoroethyl)-6,7,8.8- lelrahydro-311-pyrazoloi4,3-flisoquinolin-6-ylipyridin-3-amine 16000 14000 20 2-Theta - Scale [Continued on next page] WO 2018/077630 Al IMEDIMOM0101011MERI00 IIEMEHIIIIHMEDIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662411799P | 2016-10-24 | 2016-10-24 | |
US201662435159P | 2016-12-16 | 2016-12-16 | |
PCT/EP2017/076191 WO2018077630A1 (en) | 2016-10-24 | 2017-10-13 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903182XA true SG11201903182XA (en) | 2019-05-30 |
Family
ID=60083331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903182XA SG11201903182XA (en) | 2016-10-24 | 2017-10-13 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Country Status (35)
Country | Link |
---|---|
US (4) | US10131663B2 (en) |
EP (2) | EP3640251B1 (en) |
JP (2) | JP6744489B2 (en) |
KR (1) | KR102178692B1 (en) |
CN (2) | CN114656464A (en) |
AU (1) | AU2017349797B2 (en) |
BR (1) | BR112019007393A2 (en) |
CA (1) | CA3040040A1 (en) |
CL (1) | CL2019001077A1 (en) |
CO (1) | CO2019003950A2 (en) |
CR (1) | CR20190204A (en) |
CY (1) | CY1122566T1 (en) |
DK (2) | DK3640251T3 (en) |
DO (1) | DOP2019000104A (en) |
EC (1) | ECSP19028657A (en) |
ES (2) | ES2907759T3 (en) |
HR (1) | HRP20220255T1 (en) |
HU (2) | HUE057524T2 (en) |
IL (1) | IL266245B (en) |
JO (1) | JOP20190090B1 (en) |
LT (2) | LT3640251T (en) |
ME (1) | ME03547B (en) |
MX (1) | MX2019004685A (en) |
NI (1) | NI201900039A (en) |
NZ (1) | NZ753459A (en) |
PE (1) | PE20191078A1 (en) |
PH (1) | PH12019500830A1 (en) |
PL (2) | PL3640251T3 (en) |
PT (2) | PT3433256T (en) |
RS (1) | RS59445B1 (en) |
SG (1) | SG11201903182XA (en) |
SI (2) | SI3433256T1 (en) |
TW (1) | TWI735681B (en) |
UA (1) | UA125824C2 (en) |
WO (1) | WO2018077630A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108366996B (en) | 2015-10-01 | 2021-04-09 | 奥列马制药公司 | tetrahydro-1H-pyridine [3,4-b ] indole antiestrogens |
JP7241542B2 (en) * | 2016-04-08 | 2023-03-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
TW201815789A (en) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | Chemical compounds |
HUE057524T2 (en) | 2016-10-24 | 2022-05-28 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
UA125042C2 (en) | 2016-12-16 | 2021-12-29 | Янссен Фармацевтика Нв | Small molecule inhibitors of the jak family of kinases |
CN110248932B (en) | 2016-12-16 | 2023-03-10 | 里亚塔医药公司 | Pyrimidine tricycloalkenone derivatives for ROR γ inhibition and other uses |
JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
SI3494116T1 (en) | 2017-01-30 | 2020-02-28 | Astrazeneca Ab | Estrogen receptor modulators |
WO2019002441A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | Chemical compounds |
WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | Chemical compounds |
US11236088B2 (en) | 2017-11-14 | 2022-02-01 | Kind Pharmaceutical | Heterocyclic compounds and their application in medicine |
TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
WO2020037203A2 (en) | 2018-08-17 | 2020-02-20 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
CN109053524A (en) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | A kind of preparation method of N-Boc-3- hydroxy azetidine |
MX2022013258A (en) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Pharmaceutical formulations. |
IL297216A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
WO2021228210A1 (en) | 2020-05-15 | 2021-11-18 | 江苏先声药业有限公司 | Pyrrolidine compound and use thereof |
CN115697987A (en) * | 2020-06-12 | 2023-02-03 | 江苏先声药业有限公司 | Estrogen receptor modulator compounds and uses thereof |
EP4174059A1 (en) * | 2020-06-28 | 2023-05-03 | Medshine Discovery Inc. | Indazole-fused cyclic compound |
CN114105977B (en) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | Estrogen receptor modulator compounds and uses thereof |
KR20220107752A (en) | 2021-01-26 | 2022-08-02 | 충북대학교 산학협력단 | Pyrazoloquinoline derivatives and their use as anticancer agents |
CN116669729A (en) * | 2021-02-08 | 2023-08-29 | 贝达药业股份有限公司 | Heteroaryl piperidine derivative, and pharmaceutical composition and application thereof |
WO2023125700A1 (en) * | 2021-12-28 | 2023-07-06 | 南京明德新药研发有限公司 | Salt form and crystal form of tetrahydrocyclohepta indazole compound |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
HU229824B1 (en) | 2000-08-10 | 2014-08-28 | Pfizer Italia Srl | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
TW200716628A (en) | 2005-03-22 | 2007-05-01 | Astrazeneca Ab | Novel compounds |
FR2884252B1 (en) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY |
AR058223A1 (en) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | A COMMITTEE OF PIRAZOLOISOQUINOLINE DERIVATIVES, A PROCEDURE FOR THE PREPARATION OF SUCH COMPOUND AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND |
JP2010505961A (en) | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | Kinase inhibitor |
US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
CN102480957A (en) | 2009-05-27 | 2012-05-30 | Ptc医疗公司 | Methods For Treating Cancer And Non-neoplastic Conditions |
KR101698238B1 (en) | 2010-06-10 | 2017-01-19 | 세라곤 파마슈티컬스, 인크. | Estrogen receptor modulators and uses thereof |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
AU2011347718B2 (en) | 2010-12-24 | 2016-06-23 | Msd Oss B.V. | N-substituted azetidine derivatives |
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
BR112015029455A8 (en) | 2013-05-28 | 2020-03-17 | Astrazeneca Ab | chemical compounds, use, methods and compositions for cancer prevention or treatment |
JP6389517B2 (en) | 2013-06-19 | 2018-09-12 | セラゴン ファーマシューティカルズ, インク. | Azetidine estrogen receptor modulator and use thereof |
JP6576916B2 (en) | 2013-06-19 | 2019-09-18 | セラゴン ファーマシューティカルズ, インク. | Estrogen receptor modulators and uses thereof |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
CN107406433A (en) | 2014-12-18 | 2017-11-28 | 豪夫迈·罗氏有限公司 | Derivative for 2,3 diphenyl chromenes for the treatment of cancer |
SG11201704401TA (en) | 2014-12-18 | 2017-07-28 | Hoffmann La Roche | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
EP3233828B1 (en) * | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
WO2016189011A1 (en) | 2015-05-26 | 2016-12-01 | F. Hoffmann-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
JP2018521988A (en) * | 2015-06-16 | 2018-08-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | Piperidine derivatives, production method thereof and pharmaceutical use |
CN106518768B (en) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | Acrylic acid derivative, preparation method and medical application thereof |
CN108366996B (en) | 2015-10-01 | 2021-04-09 | 奥列马制药公司 | tetrahydro-1H-pyridine [3,4-b ] indole antiestrogens |
EP3374356A1 (en) | 2015-11-09 | 2018-09-19 | H. Hoffnabb-La Roche Ag | Tetrahydronaphthalene estrogen receptor modulators and uses thereof |
US10519148B2 (en) | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
AU2016379672A1 (en) | 2015-12-22 | 2018-06-21 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
JP7241542B2 (en) * | 2016-04-08 | 2023-03-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
US10125135B2 (en) * | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
WO2017182495A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity |
US20190233442A1 (en) | 2016-05-06 | 2019-08-01 | Xavier University Of Louisiana | Selective estrogen receptor down-regulators (serds) |
CN109415361B (en) | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | Acrylic acid derivative, preparation method thereof and application thereof in medicine |
TW201815789A (en) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | Chemical compounds |
CN107814798B (en) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-substituted acrylic acid compound and preparation method and application thereof |
US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
HUE057524T2 (en) | 2016-10-24 | 2022-05-28 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
BR102016024814A2 (en) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | Compound, Compounding Process, Pharmaceutical Composition, Compound Use, and Method of Treatment of Psychiatric Disorders and / or Sleep Disorders |
RU2019121534A (en) | 2016-12-16 | 2021-01-18 | Басф Се | PESTICIDAL COMPOUNDS |
JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
MA47399B1 (en) | 2016-12-16 | 2021-02-26 | Lilly Co Eli | Derivatives of 7-phenylethylamino-4h-pyrimido [4,5-d] [1,3] oxazin-2-one as inhibitors of the mutated form of idh1 and idh2 proteins |
UA125042C2 (en) | 2016-12-16 | 2021-12-29 | Янссен Фармацевтика Нв | Small molecule inhibitors of the jak family of kinases |
CN110248932B (en) | 2016-12-16 | 2023-03-10 | 里亚塔医药公司 | Pyrimidine tricycloalkenone derivatives for ROR γ inhibition and other uses |
CR20190289A (en) | 2016-12-16 | 2019-08-21 | Pfizer | Glp-1 receptor agonists and uses thereof |
MX2019008895A (en) | 2017-01-30 | 2019-09-13 | Chiesi Farm Spa | Tyrosine amide derivatives as rho- kinase inhibitors. |
-
2017
- 2017-10-13 HU HUE19189010A patent/HUE057524T2/en unknown
- 2017-10-13 PL PL19189010T patent/PL3640251T3/en unknown
- 2017-10-13 HU HUE17783857A patent/HUE045714T2/en unknown
- 2017-10-13 CN CN202210381693.8A patent/CN114656464A/en active Pending
- 2017-10-13 TW TW106135012A patent/TWI735681B/en active
- 2017-10-13 MX MX2019004685A patent/MX2019004685A/en unknown
- 2017-10-13 RS RSP20191371 patent/RS59445B1/en unknown
- 2017-10-13 US US15/782,904 patent/US10131663B2/en active Active
- 2017-10-13 JO JOP/2019/0090A patent/JOP20190090B1/en active
- 2017-10-13 SG SG11201903182XA patent/SG11201903182XA/en unknown
- 2017-10-13 SI SI201730111T patent/SI3433256T1/en unknown
- 2017-10-13 NZ NZ753459A patent/NZ753459A/en unknown
- 2017-10-13 DK DK19189010.2T patent/DK3640251T3/en active
- 2017-10-13 UA UAA201905126A patent/UA125824C2/en unknown
- 2017-10-13 KR KR1020197014062A patent/KR102178692B1/en active IP Right Grant
- 2017-10-13 PL PL17783857T patent/PL3433256T3/en unknown
- 2017-10-13 ES ES19189010T patent/ES2907759T3/en active Active
- 2017-10-13 LT LTEP19189010.2T patent/LT3640251T/en unknown
- 2017-10-13 CA CA3040040A patent/CA3040040A1/en active Pending
- 2017-10-13 JP JP2019520525A patent/JP6744489B2/en active Active
- 2017-10-13 DK DK17783857T patent/DK3433256T3/en active
- 2017-10-13 PT PT177838570T patent/PT3433256T/en unknown
- 2017-10-13 PT PT191890102T patent/PT3640251T/en unknown
- 2017-10-13 AU AU2017349797A patent/AU2017349797B2/en active Active
- 2017-10-13 BR BR112019007393A patent/BR112019007393A2/en unknown
- 2017-10-13 WO PCT/EP2017/076191 patent/WO2018077630A1/en active Application Filing
- 2017-10-13 SI SI201731087T patent/SI3640251T1/en unknown
- 2017-10-13 PE PE2019000845A patent/PE20191078A1/en unknown
- 2017-10-13 LT LT17783857T patent/LT3433256T/en unknown
- 2017-10-13 EP EP19189010.2A patent/EP3640251B1/en active Active
- 2017-10-13 CN CN201780064567.7A patent/CN109843888B/en active Active
- 2017-10-13 ME MEP-2019-306A patent/ME03547B/en unknown
- 2017-10-13 HR HRP20220255TT patent/HRP20220255T1/en unknown
- 2017-10-13 ES ES17783857T patent/ES2751902T3/en active Active
- 2017-10-13 EP EP17783857.0A patent/EP3433256B1/en active Active
- 2017-10-13 CR CR20190204A patent/CR20190204A/en unknown
-
2018
- 2018-10-09 US US16/155,041 patent/US10590130B2/en active Active
-
2019
- 2019-04-16 PH PH12019500830A patent/PH12019500830A1/en unknown
- 2019-04-18 CL CL2019001077A patent/CL2019001077A1/en unknown
- 2019-04-18 CO CONC2019/0003950A patent/CO2019003950A2/en unknown
- 2019-04-22 IL IL266245A patent/IL266245B/en active IP Right Grant
- 2019-04-23 EC ECSENADI201928657A patent/ECSP19028657A/en unknown
- 2019-04-23 DO DO2019000104A patent/DOP2019000104A/en unknown
- 2019-04-24 NI NI201900039A patent/NI201900039A/en unknown
- 2019-10-24 CY CY20191101110T patent/CY1122566T1/en unknown
-
2020
- 2020-01-28 US US16/774,268 patent/US10961241B2/en active Active
- 2020-07-30 JP JP2020129457A patent/JP6993477B2/en active Active
-
2021
- 2021-02-17 US US17/177,617 patent/US20210284636A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
SG11201408324QA (en) | Pyridinone and pyridazinone derivatives | |
SG11201901715UA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
SG11201901188VA (en) | Metal powder feedstocks for additive manufacturing, and system and methods for producing the same | |
SG11201810352XA (en) | New antibacterial compounds |